Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 1
2019 1
2020 1
2021 4
2022 6
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA, Fakih MG, Gholami S, Hong TS, Jaiyesimi I, Klute K, Lieu C, Sanoff H, Strickler JH, White S, Willis JA, Eng C. Morris VK, et al. J Clin Oncol. 2023 Jan 20;41(3):678-700. doi: 10.1200/JCO.22.01690. Epub 2022 Oct 17. J Clin Oncol. 2023. PMID: 36252154 Free PMC article.
PURPOSE: To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC). METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. ...In the first-line …
PURPOSE: To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC). METHODS: ASCO convened …
Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.
Wang P, Sun LL, Clark R, Hristopoulos M, Chiu CPC, Dillon M, Lin W, Lo AA, Chalsani S, Das Thakur M, Zimmerman Savill KM, Rougé L, Lupardus P, Piskol R, Husain B, Ellerman D, Shivva V, Leong SR, Ovacik M, Totpal K, Wu Y, Spiess C, Lee G, Leipold DD, Polson AG. Wang P, et al. Mol Cancer Ther. 2022 Jun 1;21(6):974-985. doi: 10.1158/1535-7163.MCT-21-0599. Mol Cancer Ther. 2022. PMID: 35364611 Free PMC article.
Immune checkpoint inhibitors have shown clinical efficacy in patients with mismatch-repair-deficient or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). However, patients with microsatellite-stable (MSS) or low levels …
Immune checkpoint inhibitors have shown clinical efficacy in patients with mismatch-repair-deficient or microsatellite instability-hi …
Immunotherapy for the treatment of colorectal cancer.
Lumish MA, Cercek A. Lumish MA, et al. J Surg Oncol. 2021 Mar;123(3):760-774. doi: 10.1002/jso.26357. J Surg Oncol. 2021. PMID: 33595891 Review.
Immune checkpoint inhibition (ICI) has transformed the management of metastatic colorectal cancer (mCRC) with mismatch-repair deficiency (dMMR) and microsatellite instability (MSI-H), though this constitutes on average less than 5% of mCRC, and ICI is ineffec …
Immune checkpoint inhibition (ICI) has transformed the management of metastatic colorectal cancer (mCRC) with mismatch-repair …
Pembrolizumab for the treatment of colorectal cancer.
Coupez D, Hulo P, Touchefeu Y, Bossard C, Bennouna J. Coupez D, et al. Expert Opin Biol Ther. 2020 Mar;20(3):219-226. doi: 10.1080/14712598.2020.1718095. Epub 2020 Feb 3. Expert Opin Biol Ther. 2020. PMID: 31952453 Review.
Introduction: Colorectal cancer (CRC) is one of the most frequent and lethal cancers in the world, and therapies are still insufficient. ...We screened all trials on PubMed and ClinicalTrials.gov and describe the most significant ones in our opinion.Expert opinion: …
Introduction: Colorectal cancer (CRC) is one of the most frequent and lethal cancers in the world, and therapies are still ins …
Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer.
Emiloju OE, Zhu M, Xie H, Jin Z, Sinicrope FA, Hubbard JM. Emiloju OE, et al. Curr Treat Options Oncol. 2023 Dec;24(12):1739-1757. doi: 10.1007/s11864-023-01142-8. Epub 2023 Nov 15. Curr Treat Options Oncol. 2023. PMID: 37966682 Review.
Standard frontline treatment of metastatic colorectal cancer (CRC) is cytotoxic chemotherapy plus a biologic agent such as an anti-EGFR monoclonal antibody (cetuximab or panitumumab) or anti-VEGF antibody (bevacizumab). ...Future studies may provide more predictive …
Standard frontline treatment of metastatic colorectal cancer (CRC) is cytotoxic chemotherapy plus a biologic agent such as an …
Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment.
Hong JH, Woo IS. Hong JH, et al. Cancer Lett. 2023 Jul 1;565:216236. doi: 10.1016/j.canlet.2023.216236. Epub 2023 May 19. Cancer Lett. 2023. PMID: 37209943 Review.
The use of immune checkpoint inhibitors (ICIs) in clinical practice for the treatment of metastatic colorectal cancer (mCRC) is currently limited to patients with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H), which comprise less …
The use of immune checkpoint inhibitors (ICIs) in clinical practice for the treatment of metastatic colorectal cancer (mCRC) i …
Adjuvant treatment of colon cancer with microsatellite instability - the state of the art.
Oneda E, Zaniboni A. Oneda E, et al. Crit Rev Oncol Hematol. 2022 Jan;169:103537. doi: 10.1016/j.critrevonc.2021.103537. Epub 2021 Nov 18. Crit Rev Oncol Hematol. 2022. PMID: 34801698 Review.
The presence of altered mismatch repair genes identify tumors with microsatellite instability (MSI) that have a better prognosis than stable tumors, but data about adjuvant chemotherapy benefit in this subgroup are compelling. ...In consideration of the dramatic res …
The presence of altered mismatch repair genes identify tumors with microsatellite instability (MSI) that have a better prognosis than …
Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases.
Margalit O, Lieberman S, Redinsky I, Halparin S, Honig N, Raskin S, Ben-Ayun M, Shacham-Shmueli E, Halpern N, Urban D, Ackerstein A, Shulman K, Ben-Ami E, Semenisty V, Purim O, Yarom N, Golan T, Boursi B, Appel S, Symon Z, Berger R, Mauro D, Krieg AM, Lawrence YR. Margalit O, et al. Clin Colorectal Cancer. 2023 Dec;22(4):442-449.e1. doi: 10.1016/j.clcc.2023.08.004. Epub 2023 Aug 9. Clin Colorectal Cancer. 2023. PMID: 37657954
INTRODUCTION: Microsatellite stable metastatic colorectal cancer (MSS mCRC) is largely refractory to immune checkpoint inhibition. ...Patients were accrued to 4 consecutive cohorts: (1) Safety run-in without radiosurgery, (2) Radiosurgery prior to intr …
INTRODUCTION: Microsatellite stable metastatic colorectal cancer (MSS mCRC) is largely refractory to immune chec …
Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer.
Yu I, Dakwar A, Takabe K. Yu I, et al. Cells. 2023 Jan 8;12(2):258. doi: 10.3390/cells12020258. Cells. 2023. PMID: 36672193 Free PMC article. Review.
Immunotherapy in colorectal cancer (CRC) has made great strides within the past decade. Immune checkpoint inhibitors are a class of immunotherapy and have been shown to greatly improve patient outcomes in mismatch repair-deficient (dMMR) CRC. Now, they are part of the stan …
Immunotherapy in colorectal cancer (CRC) has made great strides within the past decade. Immune checkpoint inhibitors are a class of i …
Clinicogenomic Characteristics and Treatment of Young-Onset Colorectal Cancer Patients Treated With Palliative Therapy in Real-World Practice.
Jeong H, Lee E, Kim D, Kim J, Kim SY, Hong YS, Kim TW, Kim JE. Jeong H, et al. Cancer Control. 2022 Jan-Dec;29:10732748221096842. doi: 10.1177/10732748221096842. Cancer Control. 2022. PMID: 35475677 Free PMC article.
METHODS: We retrospectively included patients with recurrent/metastatic colorectal cancer treated with palliative systemic therapy between 2016 and 2018. ...CONCLUSIONS: Survival outcomes with palliative systemic therapy were similar between recurrent/ …
METHODS: We retrospectively included patients with recurrent/metastatic colorectal cancer treated with palliative systemic …
20 results